SPOTLIGHT: Gilmartin testifies in Vioxx trial

Vioxx was important to Merck's financial future when the company launched the drug as other key patents were set to expire, according to testimony by the former CEO of the drug giant. But Raymond Gilmartin insisted that the company did not put profits ahead of safety in pushing the drug out into the marketplace. His videotaped deposition was played by Merck as part of its defense in a Texas trial. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.